<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813432</url>
  </required_header>
  <id_info>
    <org_study_id>EPN Diarienr. 2018/859-31</org_study_id>
    <nct_id>NCT04813432</nct_id>
  </id_info>
  <brief_title>Multiple Arterial Phase Computed Tomography Examination to Improve Detection of Tumors in the Liver and Pancreas</brief_title>
  <official_title>Low Dose Multi-arterial Phase CT Imaging for Improved Detection of Liver Tumors and Pancreatic Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine inter-subject variations of optimal late arterial phase contrast-enhancement&#xD;
      defined as the greatest difference in contrast attenuation of hepatocellular carcinoma (HCC)&#xD;
      compared to background liver parenchyma resp. pancreatic lesions compared to pancreatic&#xD;
      parenchyma. To evaluate which time-points best depict an optimal late arterial phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Many previous studies have analyzed and proposed different strategies to achieve&#xD;
      optimal contrast timing and enhancement in the late arterial phase to best depict&#xD;
      arterialized lesions in the liver and hypoattenuating tumors in the pancreas(1-12). But even&#xD;
      with the use of state-of-the-art protocols, inter-subject variations of optimal contrast&#xD;
      enhancement in liver lesions and pancreas parenchyma are still very common. The aim of this&#xD;
      study is to first analyze these alterations and to, secondly, use the newly gained knowledge&#xD;
      to design a dose-neutral multiple arterial phase protocol. An optimized arterial phase&#xD;
      protocol might improve the detection of hepatocellular carcinoma (HCC) and/or pancreatic&#xD;
      adenocarcinoma.&#xD;
&#xD;
      Purpose: To measure when the greatest difference in attenuation occurs in HCC compared to&#xD;
      background liver parenchyma resp. in pancreatic lesions vs. pancreatic parenchyma. To&#xD;
      describe the inter-subject variation of these enhancement times and to evaluate at which&#xD;
      time-points an optimal late arterial phase can be achieved. The investigators will use the&#xD;
      perfusion scanning technique, bolus-tracking and high body-weight-adjusted volumes of&#xD;
      contrast media (CM).&#xD;
&#xD;
      Anticipated results: The aim is to find the best time points for optimal CM-enhancement in&#xD;
      HCC lesions and pancreas parenchyma. The results will show the extent of the inter-subject&#xD;
      temporal enhancement differences and will be used to design an optimized late arterial phase&#xD;
      protocol for clinical practice and future studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">January 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in abdominal aorta.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in abdominal aorta.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in abdominal aorta.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in abdominal aorta.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in celiac trunc.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in celiac trunc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in celiac trunc.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in celiac trunc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in superior mesenteric artery (SMA).</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in SMA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in superior mesenteric artery (SMA).</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in SMA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in hepatic artery.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in hepatic artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in hepatic artery.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in hepatic artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in portal vein.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in portal vein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in portal vein.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in portal vein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in pancreas parenchyma.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in pancreas parenchyma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in pancreatic lesions.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in pancreatic lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in pancreas parenchyma.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in pancreas parenchyma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in pancreatic lesions.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in pancreatic lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in liver parenchyma.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in liver parenchyma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement values measured in Hounsfield units(HU) in hepatic lesions.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in hepatic lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in liver parenchyma.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in liver parenchyma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enhancement times measured in seconds in hepatic lesions.</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>Creation of time attenuation curves (TAC) in hepatic lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>highest enhancement difference between a hepatic lesion and background liver parenchyma</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>To measure the highest enhancement difference in Hounsfield units(HU) between a hepatic lesion and background liver parenchyma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time-point of highest enhancement difference between a hepatic lesion and background liver parenchyma</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>To depict the time-point of the highest enhancement difference between a hepatic lesion and background liver parenchyma by comparing their tissue attenuation curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>To measure the highest enhancement difference in Hounsfield units(HU) between a pancreatic lesion and background pancreas parenchyma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma</measure>
    <time_frame>at the time of intervention (= Multi-phasic CT scan of the abdomen)</time_frame>
    <description>To depict the time-point of the highest enhancement difference between a pancreatic lesion and background pancreas parenchyma by comparing their tissue attenuation curves</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Contrast Media</condition>
  <condition>Computed Tomography</condition>
  <condition>Imaging</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Hepatic Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Computed Tomography of the Abdomen</intervention_name>
    <description>Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.&#xD;
Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.&#xD;
Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.&#xD;
Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 consecutive patients, who are scheduled for a multiphasic liver or pancreas CT because&#xD;
        of known treatment naïve or suspected HCC or pancreatic cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients, who are scheduled for a multiphasic liver or pancreas CT because of known or&#xD;
             suspected malignancy in the liver or pancreas.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  below 50 years of age, contrast media allergy or decreased kidney function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharina Brehmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiology Department, Karolinska Huddinge university hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010 Jul;256(1):32-61. doi: 10.1148/radiol.10090908. Review.</citation>
    <PMID>20574084</PMID>
  </reference>
  <reference>
    <citation>Kondo H, Kanematsu M, Goshima S, Miyoshi T, Shiratori Y, Onozuka M, Moriyama N, Bae KT. MDCT of the pancreas: optimizing scanning delay with a bolus-tracking technique for pancreatic, peripancreatic vascular, and hepatic contrast enhancement. AJR Am J Roentgenol. 2007 Mar;188(3):751-6.</citation>
    <PMID>17312064</PMID>
  </reference>
  <reference>
    <citation>Bae KT, Heiken JP. Scan and contrast administration principles of MDCT. Eur Radiol. 2005 Dec;15 Suppl 5:E46-59. Review.</citation>
    <PMID>18637230</PMID>
  </reference>
  <reference>
    <citation>Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D, Maceroni MM, Lucchesi P, Iafrate F, Paolantonio P, Ferrari R, Laghi A. The optimal contrast media policy in CT of the liver. Part I: Technical notes. Acta Radiol. 2011 Jun 1;52(5):467-72. doi: 10.1258/ar.2011.100499. Epub 2011 Mar 17. Review.</citation>
    <PMID>21498281</PMID>
  </reference>
  <reference>
    <citation>Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D, Maceroni MM, Lucchesi P, Iafrate F, Palombo E, Paolantonio P, Ferrari R, Laghi A. The optimal contrast media policy in CT of the liver. Part II: Clinical protocols. Acta Radiol. 2011 Jun 1;52(5):473-80. doi: 10.1258/ar.2011.100500. Epub 2011 Mar 28. Review.</citation>
    <PMID>21498280</PMID>
  </reference>
  <reference>
    <citation>Fleischmann D, Kamaya A. Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am. 2009 Jan;47(1):13-26. doi: 10.1016/j.rcl.2008.10.009. Review.</citation>
    <PMID>19195531</PMID>
  </reference>
  <reference>
    <citation>Delrue L, Blanckaert P, Mertens D, De Waele J, Ceelen W, Achten E, Duyck P. Variability of CT contrast enhancement in the pancreas: a cause for concern? Pancreatology. 2011;11(6):588-94. doi: 10.1159/000334547. Epub 2012 Jan 11.</citation>
    <PMID>22237307</PMID>
  </reference>
  <reference>
    <citation>Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, Kato H, Hoshi H, Onozuka M, Moriyama N. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases. AJR Am J Roentgenol. 2006 Jul;187(1):W25-32.</citation>
    <PMID>16794136</PMID>
  </reference>
  <reference>
    <citation>Heiken JP, Brink JA, McClennan BL, Sagel SS, Crowe TM, Gaines MV. Dynamic incremental CT: effect of volume and concentration of contrast material and patient weight on hepatic enhancement. Radiology. 1995 May;195(2):353-7.</citation>
    <PMID>7724752</PMID>
  </reference>
  <reference>
    <citation>Ichikawa T, Erturk SM, Araki T. Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol. 2006 May;58(2):165-76. Epub 2006 Jan 18. Review.</citation>
    <PMID>16417983</PMID>
  </reference>
  <reference>
    <citation>Schueller G, Schima W, Schueller-Weidekamm C, Weber M, Stift A, Gnant M, Prokesch R. Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. Radiology. 2006 Nov;241(2):441-8. Epub 2006 Sep 18.</citation>
    <PMID>16982815</PMID>
  </reference>
  <reference>
    <citation>Tang A, Billiard JS, Chagnon DO, Rizk F, Olivié D, Turcotte S, Chagnon M, Lepanto L. Optimal Pancreatic Phase Delay with 64-Detector CT Scanner and Bolus-tracking Technique. Acad Radiol. 2014 Aug;21(8):977-85. doi: 10.1016/j.acra.2014.04.004.</citation>
    <PMID>25018069</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Katharina Brehmer</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>computed tomography</keyword>
  <keyword>CT angiography</keyword>
  <keyword>hepatic imaging</keyword>
  <keyword>pancreatic imaging</keyword>
  <keyword>hepatocellular cancer</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>liver</keyword>
  <keyword>pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

